Akebia Therapeutics (AKBA)CEO sold ~$134K

~$134K

Approx. value · 96K sh @ $1.39

3.32M

Holds after · shares reported

Traded

Feb 2, 2026

Filed

Feb 4, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
2. Jan 27, 2026Company filing · Form 8-K · Material agreement, New debtChanged a top executive or board member, and signed an important agreement (and 1 more item)“On January 28, 2026 (the “Effective Date”), the Company entered into an amended and restated executive severance agreement (the “Amended CEO Executive Severance Agreement”) with the Company’s President and Chief Executive Officer, John P. Butler.”
3. Feb 2, 2026 · this disclosureInsiderCEO sold ~$134K of AKBA shares in the open market

What came next

1. Feb 2, 2026Insider · 6 peopleInsiders: 14 sales (~$767K)
2. Feb 26, 2026Company filing · Form 8-K · ResultsReported its results
3. Mar 4, 2026Insider · First insider buy since Nov 2019CEO purchased ~$87K of AKBA shares in the open market
4. Mar 27, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member
5. May 7, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Akebia Therapeutics

OQRO holds no insider, Congress, fund or contract record for Akebia Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AKBA page.

Other recent filings by John P. Butler, CEO and President

• SEC Form 4 at Akebia Therapeutics (AKBA)Mar 5, 2026
• SEC Form 4 at Akebia Therapeutics (AKBA)Feb 4, 2026
• SEC Form 4 at Akebia Therapeutics (AKBA)Feb 4, 2026
• SEC Form 4 at Akebia Therapeutics (AKBA)Feb 4, 2026
• SEC Form 4 at Akebia Therapeutics (AKBA)Mar 4, 2025

The full history of John P. Butler, CEO and President is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Akebia Therapeutics

• SEC Form 4Jul 1, 2026
• SEC Form 4Mar 5, 2026
• SEC Form 4Feb 4, 2026
• SEC Form 4Feb 4, 2026
• SEC Form 4Feb 4, 2026
• SEC Form 4Feb 4, 2026

Everything OQRO holds on this company is on its AKBA page.